47results about How to "Reduce myocardial damage" patented technology

The invention belongs to the technical field of medical electronics, in particular to an extended H-bridge circuit in a defibrillator capable of generating a biphasic sawtooth discharging waveform. The H-bridge circuit consists of at least one energy storage capacitor, an inductive coil, a current sensor and a plurality of control switches, wherein the control switches are in parallel connection to form an extended H-bridge circuit switch with three vertical arm bridge circuits and two transverse arm bridge circuits; the control switches form a high-voltage discharging circuit according to a scheduled time sequence; and the high-voltage discharging circuit outputs diphasic pulse defibrillation current in a biphasic sawtooth wave pulse type to a patient to terminate ventricular fibrillation in a body and conduct rescue on the patient in time. With the adoption of the H-bridge circuit, requirements on high-voltage characteristics of a discharging bridge circuit can be lowered and device cost can be saved, individual and accurately controlled defibrillation electric energy can be provided for the patient, the success rate of cardiac shock defibrillation can be increased, and myocardial injuries in a high-voltage defibrillation process are decreased.

The invention provides a compound red sage root freeze dried powder injection containing Danshensu and its preparing process, wherein the injection comprises red sage root, notoginseng and borneol. The preparing process consists of extracting root of red rooted saliva and pseudo-ginseng to obtain red sage root extract and pseudo-ginseng extract, dissolving baras camphor with right amount of ethanol, coating with beta-cyclodextrin, charging injection for water into red sage root extract, notoginseng or red sage root and notoginseng extracts for dissolving, boiling, cooling down, filtering, mixing filtrate with baras camphor beta-CD inclusion solution, charging mannitol, adding right amount of water for injection, adjusting pH, and finally freeze-drying. In the freeze dried injection, Calculated by the total amount of ginseng saponin Rg1 (C27H32O16), ginseng saponin Rb1 and notoginseng saponin R1, the total content of notoginseng active constituent is 12.5-50.0mg/g freeze-dried powder solid.

The invention relates to a traditional Chinese medicine pill for curing amenorrhea resulted from psychotropic drugs and a preparation method thereof. The traditional Chinese medicine pill is prepared from the following bulk drugs in parts by weight: 80-100 parts of salvia miltiorrhiza bunge, 80-100 parts of peach kernel, 80-100 parts of safflower, 30-40 parts of cinnamon, 30-40 parts of fennel, 40-60 parts of folium artemisiae argyi, 40-60 parts of rhizoma cyperi, 40-60 parts of radix linderae, 40-60 parts of angelica sinensis, 40-60 parts of szechuan lovage rhizome, 40-60 parts of twotooth achyranthes root, 40-50 parts of rhizoma corydalis, 40-60 parts of bighead atractylodes rhizome and 40-60 parts of poria. The preparation method is as follows: weighting and processing 900g of the bulk drugs in parts by weight; taking 600g of the processed bulk drugs, adding 1200ml of water in the 600g of the processed bulk drugs, decocting for 40 minutes, removing dregs, decocting once again until the decoction liquid boils, decocting by slow fire and concentrating until the volume of the decoction solution is 400ml for later use; and grinding the rest 300g of the bulk drugs into fine powder, and placing the fine powder in a pelleting container, spraying the concentrated liquid in the pelleting container to prepare into water pills, taking the water pills out of the container and drying to obtain the concentrated pills. The traditional Chinese medicine pill is a pure traditional Chinese medicine preparation, has no toxic or side effect, is convenient to take and has low price.

The invention discloses application of a berberine and doxorubicine mixed preparation in preparation of a medicament against doxorubicine cardiac dysfunction or tumor. The molar concentration ratio of the berberine to the doxorubicine in the medicament is (0.625-4): 1, and the optimal ratio is 1:1. The medicament is an oral preparation or an injection preparation. The combined use of the berberine and the doxorubicine can lighten myocardial damage caused by the doxorubicine, also can play a role in inhibiting myocardial apoptosis caused by the doxorubicine, and does not weaken, even enhance the anti-tumor effect of the doxorubicine at the same time.

The invention provides a long non-coding RNA gene marker for diagnosing breast cancer chemotherapy-related myocardial injury. The long non-coding RNA is LINC01471. Through the discovery of the screening of a chip technology, compared with breast cancer patients before chemotherapy, the expression of the LINC01471 can be significantly enhanced in the blood of the patients with myocardial injury after the chemotherapy, and results can be further verified in fluorescence quantitation PCR. The beneficial effects are as follows: a molecular marker for diagnosing the breast cancer chemotherapy-related myocardial injury is provided; and whether the breast cancer patients have myocardial injury can be judged at the early stage of the chemotherapy by detecting the molecular marker, so that corresponding treatment measures can be taken as early as possible, and the possibility of the myocardial injury occurring in the breast cancer patients during treatment can be decreased. Compared with biochemical markers, the provided lncRNA marker has the characteristics of being high in sensitivity and strong in specificity.

The invention provides a locking anchoring device and a transcatheter locking anchoring system. The locking anchoring device comprises an adjusting assembly, a releasing assembly and an anchor, wherein the adjusting assembly comprises a catheter and a stop seat arranged at the far end of the catheter in a protruding mode, the stop seat is provided with a thread inlet groove for a suture to pass through, the anchor is contained at the far end of the stop seat, the far end of the anchor extends out of the stop seat, and the releasing assembly penetrates through the catheter and the stop seat and is detachably connected with the anchor. In the heart intervention process, the anchor can be contracted into the catheter, and the conveying difficulty and the damage to human tissue are reduced; and the depth of the anchor penetrating into the myocardium is limited through the stop seat, and the damage to the tissue is reduced while the anchoring force is guaranteed.

The invention discloses the application of Thonningianin A to the preparation of A drug for preventing or treating alcoholic cardiomyopathy. The Thonningianin A (TA) provided by the invention significantly reduces the plasma CK-MB content in an alcoholic cardiomyopathy model, and the reduction by high dose of TA is 38.12%, thereby restoring cardiac ejection ability and alleviating cardiac hypertrophy in alcoholic cardiomyopathy, and significantly reducing myocardial damage caused by the alcoholic cardiomyopathy model. At present, the clinical manifestations of the alcoholic cardiomyopathy areoften accompanied by cardiac dilatation and congestive heart-failure, especially left ventricular failure prevails. TA can effectively restore the increased left ventricular posterior wall thickness and myocardial damage, so TA effectively alleviates the cardiac trauma caused by an alcohol diet model.

The invention provides a compound red sage root freeze dried powder injection which comprises root of red rooted saliva, notoginseng, baras camphor through extracting root of red rooted saliva, notoginseng to obtain red sage root extract, pseudo-ginseng extract, finally dissolving baras camphor with right amount of ethanol. Calculated by the total amount of ginseng saponin Rg1 (C27H32O16), ginseng saponin Rb1, the content of notoginseng saponin R1 is 12.5-50.0mg/g of freeze-dried powder solid. Calculated by Danshensu (C9H10O5), the content of notoginseng is 2.5-15.5mg/g freeze-dried powder solid. Calculated by salvianolic acid B (C36H30O16), the content of salvia miltiorrhizae is 12.5-75.0mg/g of freeze-dried powder solid. Calculated by D-borneol (C10H180), the content of baras camphor is 12.5-62.5mg/g of freeze-dried powder solid.

The invention relates to a medical application of E1A activated gene repressor protein, in particular to a medical application of CREG1 protein or an active fragment thereof in prevention and/or treatment of sorafenib-induced myocardial injury and related diseases. Experiments prove that sorafenib intervention causes decline of the heart function of a wild type C57BL/6J mouse, meanwhile, the expression of mRNA and protein of CREG1 gene in myocardial tissue are remarkably reduced, and myocardial injury markers are remarkably increased. Exogenous administration of CREG1 recombinant protein can significantly reduce sorafenib-induced myocardial injury and cardiac dysfunction. The expression of the sorafenib-induced mouse myocardial cell programmed necrosis marker protein is obviously increased, and the death mode is programmed necrosis; exogenous administration of CREG1 recombinant protein can significantly inhibit the occurrence of programmed myocardial cell death induced by sorafenib, and the cardiac function is improved. The CREG1 recombinant protein can be used for preventing or treating myocardial injury and related diseases caused by sorafenib.

This disclosure provides LOX1 (LOX1) binding proteins such as anti-LOX1 antibodies, and compositions and methods for making these binding proteins. In certain aspects the LOX1-binding proteins provided herein, inhibit, or antagonize LOX1 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating conditions associated with atherosclerosis, thrombosis, coronary artery disease (CAD), ischemia (e.g., myocardial ischemia), infarction (e.g., myocardial infarction), acute coronary syndrome (ACS), stroke, reperfusion injury, restenosis, peripheral vascular disease, hypertension, heart failure, inflammation (e.g., chronic inflammation), angiogenesis, preeclampsia, cancer and other LOX1-mediated diseases and conditions.